The Patent Finder

Terms ending in 2039

Genmab A/S

Every in-force patent on Genmab A/S's record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 12,448,459Bispecific ANTI-CD37 Antibodies, Monoclonal ANTI-CD37 Antibodies and Methods of Use Thereof
In force
 · Medium confidence
Genmab A/SIn forceMedium confidence
US 11,008,399Antibodies
In force
 · High confidence
Genmab A/SIn forceHigh confidence
US 11,130,819Antibodies
In force
 · High confidence
Genmab A/SIn forceHigh confidence
US 12,617,854Humanized or Chimeric CD3 Antibodies
In force
 · Medium confidence
Genmab A/SIn forceMedium confidence
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited